IMM 529

Drug Profile

IMM 529

Alternative Names: IMM-529

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immuron
  • Class Anti-infectives; Polyclonal antibodies
  • Mechanism of Action Bacterial toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Clostridium-difficile-infections

Most Recent Events

  • 04 Dec 2017 Immuron has patent pending for IMM 529 in The Patent Cooperation Treaty
  • 01 Sep 2017 Phase-I/II clinical trials in Clostridium difficile infections in Israel (PO) (NCT03065374)
  • 09 Aug 2017 Immuron receives approval for a phase I trial in Clostridium difficile Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top